Literature DB >> 24079289

Predictors of statin adherence, switching, and discontinuation in the USAGE survey: understanding the use of statins in America and gaps in patient education.

Melissa Y Wei1, Matthew K Ito, Jerome D Cohen, Eliot A Brinton, Terry A Jacobson.   

Abstract

BACKGROUND: Although statins have been shown to reduce cardiovascular disease mortality, less than half of U.S. adults achieve their low-density lipoprotein cholesterol goal. In many patients initiated on a statin, adherence rates decrease over time.
OBJECTIVE: To characterize current and former statin users, identify reasons for the discontinuation or switching of statins, and identify factors associated with adherence.
METHODS: The USAGE survey is a cross-sectional, self-administered Internet-based survey of 10,138 U.S. adults fielded September to October 2011. The following statin users were identified and compared: adherent nonswitchers, adherent switchers, non-adherent switchers, and discontinuers. Univariate and multivariate models using a priori covariates for adherence and discontinuation were examined.
RESULTS: Most participants were current statin users who adhered with their prescribed statin (82.5%, n = 8371). Former statin users or discontinuers (12%, n = 1220) cited muscle pain, a side effect, as the primary reason for discontinuation (60%), followed by cost (16%), and then perceived lack of efficacy (13%). Discontinuers were less satisfied with their physicians' explanation of cholesterol treatment, more likely to use the Internet to research statins, and less likely to undergo frequent cholesterol monitoring. Among adherent statin users, the primary reasons for switching were muscle side effects (33%) and cost (32%). Individuals at risk for non-adherence included those with low household income, those who experienced muscle pain as a side effect while on statin therapy, and those taking medication for cardiovascular disease.
CONCLUSION: Statin-related muscle side effects are common and contribute significantly to rates of discontinuation, switching, and non-adherence. Improved physician patient communication about side effects and benefits of statins are necessary to improve both adherence and outcomes.
Copyright © 2013 National Lipid Association. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Adherence; Cholesterol; Compliance; Muscle symptoms; Myalgia; Side effects; Statin

Mesh:

Substances:

Year:  2013        PMID: 24079289     DOI: 10.1016/j.jacl.2013.03.001

Source DB:  PubMed          Journal:  J Clin Lipidol        ISSN: 1876-4789            Impact factor:   4.766


  63 in total

1.  Implications of the new American College of Cardiology/American Heart Association cholesterol guidelines for primary atherosclerotic cardiovascular disease event prevention in a multi ethnic cohort: Multi-Ethnic Study of Atherosclerosis (MESA).

Authors:  Joseph Yeboah; Stefan Sillau; Joseph C Delaney; Michael J Blaha; Erin D Michos; Rebekah Young; Waqas T Qureshi; Robyn McClelland; Gregory L Burke; Bruce M Psaty; David M Herrington
Journal:  Am Heart J       Date:  2015-01-06       Impact factor: 4.749

2.  Primary Care Physician Perspectives on Barriers to Statin Treatment.

Authors:  Rikki M Tanner; Monika M Safford; Keri L Monda; Benjamin Taylor; Ronan O'Beirne; Melanie Morris; Lisandro D Colantonio; Ricardo Dent; Paul Muntner; Robert S Rosenson
Journal:  Cardiovasc Drugs Ther       Date:  2017-06       Impact factor: 3.727

3.  Effects of SLCO1B1 and GATM gene variants on rosuvastatin-induced myopathy are unrelated to high plasma exposure of rosuvastatin and its metabolites.

Authors:  Xue Bai; Bin Zhang; Ping Wang; Guan-Lei Wang; Jia-Li Li; Ding-Sheng Wen; Xing-Zhen Long; Hong-Shuo Sun; Yi-Bin Liu; Min Huang; Shi-Long Zhong
Journal:  Acta Pharmacol Sin       Date:  2018-06-27       Impact factor: 6.150

Review 4.  Emerging Role of Precision Medicine in Cardiovascular Disease.

Authors:  Jane A Leopold; Joseph Loscalzo
Journal:  Circ Res       Date:  2018-04-27       Impact factor: 17.367

Review 5.  Current drug treatment of hyperlipidemia in older adults.

Authors:  Dave L Dixon; Krista L Donohoe; Kelechi C Ogbonna; Sarah M Barden
Journal:  Drugs Aging       Date:  2015-02       Impact factor: 3.923

6.  Effects of an evidence-based computerized virtual clinician on low-density lipoprotein and non-high-density lipoprotein cholesterol in adults without cardiovascular disease: The Interactive Cholesterol Advisory Tool.

Authors:  Robert C Block; Amir Abdolahi; Christopher P Niemiec; C Scott Rigby; Geoffrey C Williams
Journal:  Health Informatics J       Date:  2015-08-21       Impact factor: 2.681

Review 7.  Statins and Their Effect on PCSK9-Impact and Clinical Relevance.

Authors:  Beth A Taylor; Paul D Thompson
Journal:  Curr Atheroscler Rep       Date:  2016-08       Impact factor: 5.113

8.  Prevalence and Management of Symptoms Associated With Statin Therapy in Community Practice: Insights From the PALM (Patient and Provider Assessment of Lipid Management) Registry.

Authors:  Ann Marie Navar; Eric D Peterson; Shuang Li; Jennifer G Robinson; Veronique L Roger; Anne C Goldberg; Salim Virani; Peter W F Wilson; Michael G Nanna; L Veronica Lee; Joseph Elassal; Tracy Y Wang
Journal:  Circ Cardiovasc Qual Outcomes       Date:  2018-03

Review 9.  Statins and Cataracts--a visual insight.

Authors:  Jeanne M Dobrzynski; John B Kostis
Journal:  Curr Atheroscler Rep       Date:  2015       Impact factor: 5.113

Review 10.  Approach to Statin Use in 2016: an Update.

Authors:  P Elliott Miller; Seth S Martin
Journal:  Curr Atheroscler Rep       Date:  2016-05       Impact factor: 5.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.